GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AEterna Zentaris Inc (TSX:AEZS) » Definitions » Total Inventories
中文

AEterna Zentaris (TSX:AEZS) Total Inventories

: C$0.09 Mil (As of Dec. 2023)
View and export this data going back to 1995. Start your Free Trial

AEterna Zentaris's total inventories for the quarter that ended in Dec. 2023 was C$0.09 Mil. AEterna Zentaris's average total inventories from the quarter that ended in Sep. 2023 to the quarter that ended in Dec. 2023 was C$0.11 Mil.

In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. AEterna Zentaris's Net-Net Working Capital per share for the quarter that ended in Dec. 2023 was C$4.22.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. AEterna Zentaris's Days Inventory for the three months ended in Dec. 2023 was 132.50.

Inventory Turnover measures how fast the company turns over its inventory within a year. AEterna Zentaris's Inventory Turnover for the quarter that ended in Dec. 2023 was 0.69.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. AEterna Zentaris's Inventory-to-Revenue for the quarter that ended in Dec. 2023 was 0.65.


AEterna Zentaris Total Inventories Historical Data

The historical data trend for AEterna Zentaris's Total Inventories can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AEterna Zentaris Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Total Inventories
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.58 0.03 0.09 0.31 0.09

AEterna Zentaris Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Total Inventories Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.31 0.31 0.12 0.12 0.09

AEterna Zentaris Total Inventories Calculation

Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.


AEterna Zentaris  (TSX:AEZS) Total Inventories Explanation

Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.

1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.

AEterna Zentaris's Net-Net Working Capital Per Share for the quarter that ended in Dec. 2023 is

Net-Net Working Capital Per Share (Q: Dec. 2023 )
=(Cash And Cash Equivalents+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(45.636+0.75 * 0.09+0.5 * 0.089-25.249
-0-0)/4.85588
=4.22

2. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

AEterna Zentaris's Days Inventory for the three months ended in Dec. 2023 is calculated as:

Days Inventory=Average Total Inventories (Q: Dec. 2023 )/Cost of Goods Sold (Q: Dec. 2023 )*Days in Period
=0.106/0.073*365 / 4
=132.50

3. Inventory Turnover measures how fast the company turns over its inventory within a year.

AEterna Zentaris's Inventory Turnover for the quarter that ended in Dec. 2023 is calculated as

Inventory Turnover=Cost of Goods Sold (Q: Dec. 2023 ) / Average Total Inventories (Q: Dec. 2023 )
=0.073 / 0.106
=0.69

4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

AEterna Zentaris's Inventory to Revenue for the quarter that ended in Dec. 2023 is calculated as

Inventory-to-Revenue=Average Total Inventories (Q: Dec. 2023 ) / Revenue (Q: Dec. 2023 )
=0.106 / 0.162
=0.65

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.

When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.

Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.


AEterna Zentaris Total Inventories Related Terms

Thank you for viewing the detailed overview of AEterna Zentaris's Total Inventories provided by GuruFocus.com. Please click on the following links to see related term pages.


AEterna Zentaris (TSX:AEZS) Business Description

Traded in Other Exchanges
Address
222 Bay Street, Suite 3000, PO Box 53, c/o Norton Rose Fulbright Canada, LLP, Toronto, ON, CAN, M5K 1E7
AEterna Zentaris Inc is a biopharmaceutical company commercializing & developing therapeutics & diagnostic tests. The company's product, Macrilen (macimorelin), is the oral test indicated for the diagnosis of adult growth hormone deficiency (GHD). Macrilen is marketed in the U.S. through a license agreement with Novo Nordisk & the company receives royalties on sales. Aeterna owns all rights to macimorelin outside of the U.S. & Canada. It is leveraging the clinical success & safety profile of macimorelin to develop it for the diagnosis of child-onset GHD. The company's geographical segments include Switzerland, Ireland, Denmark, and others, of which nearly all of its revenue comes from Switzerland.